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The	 aim	 of	 this	 paper	 is	 to	 introduce	 current	 advances	 in	 technology	
that	could	enable	the	development	of	fully	drinkable	and	autonomous	
bio-electronic	 CMOS	 sensors	 in	 the	 form	of	 dust	 particles,	 capable	 of	
identifying	 the	 source	 of	 a	 disease	 by	 targeting	 a	 specific	 region	 in	
organs	 and	 tissue	 such	 as	 a	 tumor	 mass	 and	 automatically	 sending	
diagnostic	information	wirelessly	outside	the	body.	We	call	this	swarm	
of	sensing	dust	particles	‘Body	Dust’.	A	diagnostic	system	in	the	form	of	
Body	Dust	would	need	to	be	small	enough	to	support	free	circulation	in	
human	tissues,	which	requires	a	total	size	of	less	than	10	μm3,	in	order	
to	 mimic	 the	 typical	 sizes	 of	 a	 blood	 cell	 (e.g.,	 red	 cells	 have	 the	
diameter	 around	7	μm).	Whilst	with	present	 state-of-the-art	 in	CMOS	
technology,	 this	 requirement	 in	 terms	 of	 size	 is	 currently	 un-feasible,	
recent	 research	 has	 advanced	 technology	 such	 that	 we	 can	 begin	 to	
work	 towards	 such	 an	 approach.	 Therefore,	 we	 present	 here	 the	
current	limits	of	CMOS	technology	as	well	as	the	challenges	related	to	
the	 development	 of	 such	 a	 system.	 Towards	 this	 goal,	 this	 article	
presents	 the	 theoretical	 feasibility	 to	 obtain	 the	 first	 ever-conceived	
sub-10	 μm	 Bio/CMOS	 integrated	 circuit	 with	 biosensing	 capability	 to	
provide	diagnostic	telemetry	once	self-located	in	human	tissue.		
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	In	 the	 last	 10	 years,	 the	 field	 of	 microelectronics	 has	 progressed	significantly	due	to	the	introduction	of	nano-scale	CMOS	technology	for	 integrated	 circuits	 (IC),	 guaranteeing	 robustness	 and	 reliability	though	 novel	 circuit-design	 techniques	 (1).	 This	 amazing	progression	has	also	been	seen	in	the	design	of	CMOS	interfaces	for	biosensing,	allowing	realisation	fully	integrated	micro-scale	sensing	systems.	 (2).	 Alternatively,	 the	 development	 of	 nano-fabricated	devices	 has	 paved	 the	 way	 of	 new	 kinds	 of	 biosensing	 (3),	 while	offering	 the	 possibility	 of	 fusion	 with	 also	 sample	 preparation	and/or	 amplification	 to	 create	 fully	 autonomous	 sensing	 systems	(4).	By	pushing	forward	this	trends	in	CMOS	and	nano-fabrication	of	sensors,	 we	 can	 begin	 to	 conceptualise	 the	 development	 of	 an	extremely	 integrated	 system	 the	 same	 size	 as	 a	 human	 cell	 and	which	 also	 contains	 all	 the	 electronics	 for	 in-body	 sensing	 and	wireless	telemetry	of	data	and	whose	form	factor	is	so	small	that	it	could	exist	as	a	swarm	of	dust	particles	in	a	diagnostic	solution	that	could	be	drunk	by	a	patient	requiring	diagnosis.		Working	 towards	 this	 goal,	 in	 this	 paper	 we	 introduce	 the	theoretical	 feasibility	 of	 the	 first	 ever	 conceived	 sub-10	 μm	Bio/CMOS	 integrated	 circuit	 with	 biosensing	 capability	 useful	 to	provide	 diagnostic	 telemetry	 once	 self-located	 in	 a	 human	 tissue	after	 being	drunk	by	 the	 patient.	 The	 core	 idea	 is	 here	 to	 propose	the	design	of	a	fully	packaged	CMOS	cube	as	illustrated	in	Figure	1,	which	 integrates	 the	 most	 compact,	 in	 terms	 of	 area,	 integrated	circuits	 ever	 built.	 This	 CMOS	 cube	 has	 to	 be	 capable	 of	 providing	diagnostics	 through	 sensing	 of	 specific	 molecules,	 data-telemetry,	low-power	consumption,	and	biocompatibility.	An	adapted	energy-harvesting	 system	 to	 provide	 enough	 power	 is	 also	 required.	 	We	also	envisage	the	use	of	the	most-robust,	smallest,	and	commercially	available	CMOS	nodes	(e.g.,	5	nm)	as	well	as	the	addition	of	special	functions	to	the	CMOS	architecture	for	dealing	with	post-processing	heterogeneous	integration	of	further	nanostructures.	
	
Fig.	 1:	 Illuastration	 of	 the	 conept	 of	 CMOS	 Body	 Dust.	 Shown	 are	diagnostic	sensing	cubes	of	10	μm3	comparable	with	 the	size	of	 red	blood	cells.		These	 nanostructures	 are	 typically	 required	 to	 form	 sensors	 with	increased	 sensitivity	 for	 diagnostics	 (5).	 Once	 realized,	 this	bioelectronics	system	will	have	the	form	of	Body	Dust	due	to	its	μm-scale	 size	 and	 be	 capable	 of	 real-time	 diagnostics	 inside	 human	tissues	 as	well	 as	 in	 organs.	 Towards	 realising	 such	 a	 system,	 this	research	 paper	 provides	 a	 comprehensive	 investigation	 of	 the	options	along	the	design	path	of	such	a	drinkable	bio-electronic	dust	system	that	is	capable	of	self-identifying	a	target	body-region	source	of	 a	 disease	 (e.g.,	 a	 tumor	 mass)	 and	 automatically	 sending	wirelessly	diagnostic	data	outside	the	body.		
System	Concept	A	diagnostic	system	with	the	mentioned	features	is	envisaged	to	be	of	the	form	a	myriad	of	small	particles,	each	one	with	a	total	size	of	less	than	10	μm3.	This	is	required	for	passing	the	gut-wall	barrier	by	the	mechanism	of	 cells	 internalization	 (as	well	 as	blood	cells)	 and,	therefore,	diffusing	in	the	human	tissues.	Once	diffused	in	the	body,	these	free	circulating	diagnostic	particles	need	to	have	the	capability	of	 self-targeting	 a	 specific	 body	 region	 (e.g.,	 a	 tumor	 mass).	 Once	onto	 the	 body-mass,	 these	 particles	 need	 to	 start	 providing	diagnostics	 through	 telemetry.	The	 telemetric	diagnostics	needs	 to	be	at	level	of	specific	molecules	in	order	to	monitor	the	trend	of	the	disease	 (e.g.,	 by	measuring	 specific	 biomarkers	 or	metabolites)	 as	well	 as	 to	 provide	 feedback	 for	 personalized	 medicine	 (e.g.,	 by	measuring	 specific	 therapeutic	 compounds).	 Toward	 that	 aim,	 the	research	path	needs	to	develop	along	the	following	main	branches:	(i)	 demonstrating	 the	 feasibility	 of	 designing	 the	 most	 compact	CMOS	IC	allowing	 in	any	case	all	 the	required	 functions	 to	support	telemetric	diagnostics	as	well	as	any	function	required	for	its	initial	setting;	 (ii)	 demonstrating	 the	 feasibility	 of	 designing	 of	 a	 proper	system	to	address	the	powering	issues	arising	at	such	small	scale	of	integration,	 (iii)	 showing	 monolithic	 integration	 with	 the	 right	biomaterials	 in	order	 to	assure	specificity	 for	 the	diagnostics	aims,	(iv)	showing	monolithic	integration	with	the	right	nanomaterials	in	order	 to	 assure	 enough	 sensitivity	 for	 the	 diagnostics	 aims;	 (v)	demonstrating	the	design	of	a	biocompatible	packaging	to	avoid	any	inflammatory	 reaction	 by	 the	 human	 body;	 (vi)	 assuring	 a	 further	coating-function	to	target	the	specific	body	mass;	(vii)	assuring		
	
Fig.	 2:	 Concept	 of	 the	 CMOS	 cube	 for	 Body	 Dust	 with	 an	electrochemical	sensor	on	top	of	the	last	metal-layer	and	powering	antennas	realised	by	using	all	metal-layers.		another	coating-function	to	allow	the	internalization	in	M	cells	and	dendritic	cells,	special	cells	devoted	to	internalise	big	bio-structures	(e.g.,	liposomes	with	sizes	up	to	2.5	μm),	and,	thus,	to	allow	passing	through	the	barrier	of	the	gut-wall.	With	the	present	state-of-the-art	in	CMOS	technology,	targeting	a	total	size	of	 less	than	10	μm3	looks	to	 be	 un-feasible.	 However,	 recent	 findings	 obtained	 over	 the	 last	very	 few	years	open	the	possibility	 for	realizing	such	a	CMOS	cube	we	propose	in	form	of	Body	Dust.	In	fact,	compact	CMOS	circuits	for	glucose	sensing	at	a	size	of	0.36-mm2	have	been	realised	in	2012	by	using	 the	 0.13-μm	CMOS	 process	 (6)	 and	 similar	 designs	 could	 be	further	 reduced	 in	 size	 by	 both	 further	 simplifying	 the	 design	 and	then	fabricating	in	smaller	nodes	(e.g.,	with	CMOS	5-nm	or	smaller).	Micro-coils	with	 lateral	 sizes	 from	200	μm	 (7)	 down	 to	 50	μm	 (8)	have	 been	 published	 in	 2016	 for	 successfully	 powering	 in	implantable	 micro-stimulators.	 Biosensors	 realized	 on	 CMOS	 dies	with	 radii	 of	 the	 working	 electrodes	 down	 to	 2.5	 μm	 have	 been	published	 in	 2014	 and	 successfully	 tested	 for	 glucose	 detection	thank	 to	 platinum	 nanostructures	 (9).	 We	 successfully	 realized,	tested,	 and	published	 in	2016	 a	 biocompatible	 packaging	obtained	with	 an	 epoxy-resin	 to	 protect	 telemetric	 diagnostic	 devices	 fully	implanted	in	mice	(10).	The	use	of	affinity	ligands	for	specific	uptake	to	 targeted	 disease-cells	 is	 one	 of	 the	 proposed	 strategy	 to	 assure	active	 targeting	 in	 anticancer	 therapies	 (11).	 The	 mechanism	 of	internalization	 provided	 by	 M	 cells	 and	 dendritic	 cells	 is	 a	 well-known	phenomenon	(12)	that	allows	active	transport	through	cells-layers	 of	 bio-structures	 with	 also	 size	 in	 few	 μm	 (e.g.,	 liposomes	present	size	ranging	from	0.025	μm	to	2.5	μm)	(13).			Moreover,	it	is	also	well-known	that	the	gut	permeability	is	usually	augmented	in	Crohn's	disease-patients	and	ulcerative	colitis	(14).		
	
	
	 	 	 	
Fig.	3:	(A)	Diagram	of	a	three-electrode	electrochemical	cell	with	a	potentiostat;	and	(B)	the	conceptual	diagram	of	a	readout	IC	to	read	the	sensor	current	(reprinted	from	(25)).		Considering	 the	 research	 described	 shows	 that	 mechanisms	 are	possible	for	realisation	of	Body	Dust	particles,	we	therefore	propose	in	 this	 paper	 the	 concept	 of	 a	 CMOS	 cube	 of	 10	μm3	 as	 shown	 in	figure	2	as	 first	prototype	 in	order	 to	 investigate	all	 the	difficulties	related	to	developing	a	system	with	such	an	extremely-small	size	for	an	active	biosensing	device.	For	such	a	demonstration,	we	will	start,	first,	 by	 introducing	 the	 state-of-the-art	 about	 the	 main	 issues	related	 to	 this	 new	 design:	 integrated	 potentiostats,	 powering	systems,	 nano-biosensors	 on	 chip	 and	 packaging.	 Then,	 we	 will	propose	 an	 original	 design	 for	 the	 proposed	 system,	 including	heterogeneous	 integration	 of	 sensors	 and	 packaging.	 The	 paper	closes	with	discussion	on	the	proposed	design	and	conclusions.			
State-of-the-art:	the	potentiostats	Amperometric	 methods	 are	 one	 of	 the	 most	 widely	 adopted	 and	commonly	used	approaches	for	biosensing	applications.	Their	mode	of	 operation	 relies	 on	 the	 detection	 of	 signals	 in	 the	 form	 of	 an	electric	 current	 that	 is	 proportional	 to	 the	 concentration	 of	 the	target	 biomolecule.	 Initiating	 a	 redox	 reaction	 normally	 generates	the	current.		As	shown	in	Figure	3	(A),	to	initiate	the	reaction,	a	cell	potential	(or	voltage)	 is	 normally	 applied	 to	 a	 reference	 electrode	 (RE)	 to	generate	a	cell	current	measured	through	a	working	electrode	(WE).	A	 circuit	 called	 the	 potentiostat,	 is	 typically	 required	 to	 apply	 this	voltage	and	measure	the	current.	Fully	integrated	potentiostats	aim	to	 combine	 surface	 electrodes	 and	 instrumentation	 working	 as	 a	lab-on-chip	 device	 to	 detect	 various	 electrochemical	 species.	 As	shown	 in	 Figure	 3	 (B),	 the	 instrumentation	 to	 read	 the	 generated	current	 typically	 requires	 a	 transimpedance	 amplifier	 (TIA)	 to	
Table	1:	Performance	of	some	fully	integrated	potentiostats		
convert	 the	 cell	 current	 to	 a	 voltage,	which	 is	 then	 sampled	 by	 an	analogue	 to	 digital	 converter	 (ADC)	 for	 data	 transmission.	 In	implantable	 applications,	 in	 addition	 to	 having	 low-power,	important	 parameters	 of	 the	 potentiostat	 are	 the	 input	 resolution	and	dynamic	range,	which	defines	 the	range	of	current	 that	can	be	sensed	 as	 well	 as	 the	 smallest	 detectable	 current.	 An	 ADC	 is	sometimes	integrated	with	the	potentiostat	IC	in	order	to	provide	a	digital	output	that	can	be	directly	transmitted	wirelessly.			A	 summary	 of	 the	 state-of-the	 art	 of	 potentiostats	 found	 in		literature	with	 their	 readout	 circuits	and	achieved	specifications	 is	presented	in	Table	1.	The	circuit	configurations	for	readout	usually	fall	 into	one	of	 the	 following	 four	 categories:	 (i)	 resistive	 feedback	transimpedance	 amplifier	 (TIA),	 (ii)	 sigma-delta	 modulator,	 (iii)	switched-capacitor	 op-amp	 integrator,	 and	 (iv)	 current-mode	readout.	 The	 resistive	 feedback	 TIA	 is	 the	 simplest	 circuit	 to	implement	as	 it	measures	 in	continuous	 time	and	 it	provides	good	input	current	 resolution.	The	circuits	 in	 the	sigma-delta	modulator	class	 have	 the	 widest	 input	 dynamic	 range	 without	 the	 need	 for	changing	 the	 gain.	 The	 switched	 capacitor-integrator	 converts	 the	biosensor	current	response	into	voltage,	which	then	goes	through	a	programmable-gain-amplifier	 to	 support	 high	 dynamic	 range.	Finally	the	current-mode	circuits	use	current	mirrors	and	conveyors	to	 produce	 a	 copy	 of	 the	 sensor	 current	 and	 to	 amplify	 it	 before	quantising	it	with	the	ADC.				In	 terms	 of	 achieving	 minimum	 area	 through	 integrated	 circuit	design,	a	CMOS	instrumentation	system-on-chip	for	glucose	sensing	has	been	successfully	realised	in	2012	with	a	lateral	size	around	600	μm	(total	area	of	0.36-mm2)	(6).	This	IC	has	been	fabricated	by	using	a	 0.13-μm	 CMOS	 process,	 while	 further	 simplified	 architectures	fabricated	 by	 using	 smaller	 CMOS	 nodes	 (e.g.,	 with	 CMOS	 5-nm)	could	reduce	 the	area	 further.	Another	example	 is	a	prototype	of	a	time-to-digital	 converter	 fabricated	 in	 65nm	 CMOS,	 achieving	 a	lateral	 size	 of	 only	 245	 μm	 (total	 area	 of	 0.06-mm2)	 (26),	 while	 a	brain	stimulator	has	been	very	recently	proposed	with	lateral	sizes	of	220	μm	x	180	μm	(total	area	less	than	0.04	mm2)	and	fabricated	in	0.18	μm	CMOS	technology	(7).		
	
State-of-the-art:	micro-fabricated	coils		A	coil	with	sizes	of	200	μm	x	200	μm	was	very-recently	 fabricated	off-chip	 and	 then	 used	 to	 power	 one	 of	 the	 previously	mentioned	CMOS	IC	designed	with	very	small	lateral	sizes.	The	power	delivered	to	 the	 system	 was	 0.016	 mW	 (7),	 which	 is	 close	 to	 the	 power	required	 by	 quite	 complex	 CMOS	 potentiostats	 for	 multiplexed	detection	of	human	metabolism	(27).	On	the	other	hand,	coils	with	smaller	 size,	 down	 to	 50	 μm,	 have	 been	 proposed	 in	 2016	 for	powering	 implantable	 brain	 stimulators	 (8).	 In	 this	 second	approach,	 the	 micro-coil	 was	 fabricated	 in	 two	 versions:	 a	 first	version	was	obtained	by	a	copper	trace	(10	μm	wide	×	2	μm	thick)	directly	 fabricated	 on	 a	 silicon	 substrate	 and	 passivated	with	 300	nm	 of	 SiO2.	 A	 second	 version	 was	 indeed	 realized	 by	 carefully	bending	an	ultra-fine	wire	of	 copper	with	only	50-μm	 in	diameter.	The	realized	coils	have	a	profile	of	50	μm	×	100	μm	and	a	length	of	2000	 μm.	 The	 coil	 realized	 with	 the	 micro-wire	 supported	 a	stronger	current	even	though	was	tough	to	get	very	sharp	structures	as	 obtained	 with	 the	 coil	 micro-fabricated	 directly	 on	 silicon.	 The	power	 delivered	 by	 these	 new	 micro-coils	 compare	 favourably	 to	power	 levels	 around	 0.5	mW,	 thus	well	 enough	 for	 also	 powering	quite	 complex	 CMOS	 full-systems	 for	 multiplexed	 detection	 of	human	metabolism	(27).		
State-of-the-art:	nanosensors	and	biosensors		To	 provide	 diagnostics	 on	 specific	 molecules	 (e.g.,	 cancer	biomarkers,	 human	 metabolites,	 anti-cancer	 therapeutic	compounds),	 we	 can	 transfer	 specific	 recognition	 functions	 to	 the	working	electrodes	shown	in	Figure	2.	This	is	typically	obtained	by	incorporating	probe-proteins	 that	 specifically	 recognise	 the	 target-	molecules	with	respect	to	the	sensing	aim.	For	example,	Antibodies	(28)	 or	 Aptamers	 (29)	 are	 extensively	 used	 for	 detecting	 cancer	biomarkers,	oxidases	(a	class	of	enzymes)	are	proposed	for	several	human	 metabolites	 (30),	 cytochromes	 P450	 (another	 class	 of	enzymes)	are	suggested	for	anticancer	therapeutic	compounds	(31).	
In	 many	 cases,	 protein	 based	 amperometric	 biosensors	 face	 as	limiting	 factor	 the	 electron	 transfer	 rate	 toward	 the	 working	electrode.	To	improve	electron	transfer	rate,	many	studies	propose	the	 characterization	 of	 protein	 sensing-systems	 working	 on	nanostructured	 electrodes.	 For	 example,	 multi-walled	 carbon	nanotubes	 (MWCNT)	 are	 used	 for	 structuring	 carbon-paste	 based	(32)	 as	well	 as	 gold	 electrodes	 (33).	 The	 typical	 obtained	 surfaces	are	 similar	 to	 that	 shown	 in	 the	 following	 Figure	 4,	 where	 highly	dense	 bundles	 of	 carbon	 nanotubes	 were	 formed	 on	 the	 sensing	surface	by	drop	casting	solutions	with	mono-disperse	nanotubes.		
	
			
Fig.	4:	(A)	Multi-walled	carbon	nanotubes	on	sensing	electrodes;	and	(B)	detection	of	a	chemotherapy	compound	with	or	without	multi-walled	carbon	nanotubes	(reprinted	by	(31))			Such	 surfaces	 with	 highly	 dense	 bundles	 of	 carbon	 nanotubes	turned	out	to	be	extremely	powerful	in	terms	of	sensor	performance	for	 both	 enzyme-mediated	 and	 direct	 detection	 of	 human	metabolites.	 For	 example,	 in	 case	 of	 anti-cancer	 drugs,	 it	 was	possible	to	achieve	sensitivity	in	the	right	pharmacological	range	of	concentrations	only	thank	to	the	integration	of	such	nano-materials,	as	 shown	 in	Figure	4	 (B)	 for	 the	case	of	a	very	well-known	cancer	chemotherapy	 compound	 (the	 cyclophosphamide,	 CP).	 Of	 course,	different	 nanomaterials	 transferred	 or	 growth	 on	 metal	 surfaces	return	 different	 sensing	 performance.	 The	 glucose	 detection	 has	been	differently	improved	by	different	nanomaterials	as	per	data	in	Table	2.	Several	approaches	have	been	proposed	along	the	last	years	to	incorporate	Carbon	Nanotubes	(CNT)	onto	the	sensing	electrodes.	CNT	may	be	 integrated	on	metal	 surfaces	by	direct	CVD	 (Chemical	Vapour	 Deposition)	 growth	 (42),	 micro-spotting	 (43),	 or	electrochemical	 deposition	 (41).	 Graphene	 like	 nanostructures	 are	integrable	 on	 metals	 again	 by	 direct	 CVD	 growth	 too	 (44),	 while	nano-platinum	is	usually	obtained	by	electrodeposition	(38).	Thank	to	 platinum	 nanomaterials	 easily	 integrated	 on	 electrochemical	CMOS	devices,	biosensors	directly	realized	on	top	of	the	CMOS	dies	with	 radii	 of	 the	 working	 electrodes	 down	 to	 2.5	 μm	 have	 been	published	in	2015	and	successfully	tested	for	glucose	detection	(9).	With	this	kind	of	nano-structuration,	electrodes	with	sizes	of	only	5	μm	in	diameter	were	found	with	a	sensitivity	 increased	by	a	 factor	larger	than	400	times	(9).		
	
Fig	5:	Morphology	of	electrodeposited	Pt	nanostructured	films	(reprinted	from	(38).		With	the	electrochemical	deposition,	we	have	successfully	obtained	sensors	 with	 high-performance	 by	 also	 transferring	 nano-Pt	structures	 (Figure	 5),	 by	 reaching	 a	 maximum	 sensitivity	 of	 51.6	μA/(mM	 cm2)	 (38).	 With	 this	 nano-Pt,	 we	 have	 detected	 several	metabolites	of	extreme	interest	in	biomedical	applications,	including	but	not	limited	to	glucose	(as	shown	in	Figure	6)	and	potassium	(5)	in	 undiluted	 cell	 culture	 media.	 Over	 the	 recent	 years,	 we	 have	detected	 several	 other	 endogenous	 and	 exogenous	 molecules	related	to	human	metabolism	and	cancer	diagnostics	by	combining	nanostructured	 sensors	 and	probe-proteins.	 For	 example,	we	have	successfully	 obtained	 the	 best	 ever	 realised	 aptamers	 based	biosensors	for	the	Prostate	(cancer)	Specific	Antigen,	the	PSA	(3)	as	well	as	an	antibodies	based	biosensors	for	another	important	cancer	marker,	 the	 grow	 factor	 VEGF	 (45).	 We	 have	 detected	 several	anticancer	chemotherapy	compounds,	including	cyclophosphamide,	ifosfamide,	 ftorafur,	 and	 etoposide,	 both	 in	 buffer	 samples	 and	 in	human	serum,	within	the	pharmacological	ranges	(46).			
State-of-the-art:	nanosensors	on	chip	In	 some	 cases,	 the	 designed	 IC	 needs	 to	 directly	 integrate	nanostructured	biosensors	in	order	to	provide	high	performance	on	real	human	samples.	In	such	cases,	a	possible	design-solution	is	the	opening	 of	 the	 IC	 die	 to	 realise	 the	 sensing	 electrodes	 by	 metal	evaporation	directly	on	top	of	the	IC,	as	shown	by	the	SEM	image	in	Figure	7.	In	this	manner,	the	sensing	electrodes	are	directly	exposed	to	 the	 bio-interface	 as	 well	 as	 in	 direct	 electrical	 contact	 to	 the	underneath	CMOS	metal	layers.	This	solution	has	been	proposed	to	enables	 a	 close	 positioning	 of	 the	 electronics	 to	 the	 sensing	chambers.	 Figure	 8	 shows	 a	 biochip	 designed	 for	 DNA	 detection,	where	the	location	of	the	CMOS	IC	is	extremely	close	to	the	sensing	interface,	assuring	the	best	possible	signal-to-noise	ratio.			
	
Fig.	7:	Sensing	electrodes	directly	created	on	top	of	the	last	metal	layer	(from	(47))		
	
Fig.	6:	Amperometric	detection	by	cyclic	voltammetry	of	glucose	in	cell	media	(reprinted	from	(38)).			This	 kind	 of	 full	 integration	 of	 biosensing	 devices	 and	 CMOS	architectures	not	only	improves	signal/noise	ratio,	and	accordingly	provide	smaller	limit-of-detections	(LOD),	but	also	address	the	need	of	smaller	biochips	for	portable,	wearable,	implantable,	or	injectable	electronics	 for	human	health	continuous	monitoring	(27).	Over	 the	last	years,	we	have	successfully	achieved	several	milestones	toward	a	 deep	 integration	 of	 heterogeneous	 structures	 for	 sensing	application	 with	 CMOS	 designed	 potentiostats.	 For	 example,	 our	group	 achieved	 for	 the	 first	 time	 the	 fabrication	 of	 carbon	nanostructures	 with	 sufficiently	 good	 yield	 at	 450ºC	 (44),	 a	relatively	lower	temperature	compatible	for	integration	with	CMOS	technology	 (48),	 since	 IC	 dies	 and	 their	 adhesive	 materials	 are	usually	 start	 melting	 at	 temperatures	 as	 high	 as	 500	 °C	 (49).	 We	have	 also	 demonstrated	 an	 alternative	 method	 to	 transfer	nanomaterials	 by	micro	 spotting.	 However,	 it	 turned	 out	 that	 this	method	is	limiting	the	sensing	performance	(sensitivities	about	0.46	μA/mM	cm2)	due	to	the	presence	of	required	polymers	(43).	While	chemical	vapour	(44)	or	electrochemical	(41)	depositions	return	the	best	 sensitivities	 in	 transferring	 carbon	 nano-materials.	 The	biosensing	 performance	 of	 these	 systems	 have	 been	 improved	 by	also	 integrating	MWCNT	by	drop	 casting	 (41)	 or	 electrodeposition	(30).	By	using	 these	approaches,	we	have	succeeded	 in	monitoring	several	 human	 molecules	 by	 integrating	 proper	 proteins,	 e.g.	enzymes	 from	 the	 families	 of	 oxidases	 or	 cytochromes	 P450.	 We	have	detected	endogenous	metabolites,	e.g,	glucose	and	lactate	(27),	as	well	as	exogenous	therapeutic	compounds,	such	as	etoposide	and	mitoxantrone	 (41),	 or	 etodolac	 (50).	 Fully	 implantation	 in	 mouse	has	been	successfully	verified	too	with	the	detection	of	glucose	and	paracetamol	 (51),	 as	models	 for	 the	 detection	 of	 both	 endogenous	biomarkers	 and	 exogenous	 therapeutic	 drugs.	 We	 have	 also	significantly	 contributed	 to	 the	 integration	of	CMOS	 ICs	with	 these	kinds	 of	 protein-based	 electrochemical	 biosensors,	 especially	 for	implantable	 devices.	 Figures	 9	 shows	 two	 fully	 integrated	 multi-panel	 systems	we	 have	 designed	 and	 realized	 very	 few	 years	 ago.	Both	the	systems	present	several	biosensors	and	also	 include	a	pH	sensor	and	a	temperature	sensor.			
	
Fig.8:	Integrated	BioChip	with	128	couples	of	electrodes	for	DNA	detection	(from	(52))	
State-of-the-art:	biocompatible	packaging	In	 case	 of	 implantable	 or	 injectable	 electronics,	 issues	 on	biocompatibility	take	a	major	role,	as	the	hosting	body	needs	to	be	protected	by	any	inflammatory	reaction.	In	this	respect,	several	tens	of	 years	 of	 research	 and	 development	 about	 implantable	 devices	then	 successfully	 introduced	 into	 the	 market	 (e.g.,	 pacemakers	 or	systems	for	deep	brain	stimulation)	have	proposed	several	solutions	to	 obtain	 biocompatible	 packaging.	 For	 example,	 fully	 sealed	packaging	has	been	proposed	 in	biocompatible	 silicone	 (53),	while	semi-permeable	membranes	has	been	proposed	for	sensing	aims	by	using	polycarbonate	(54)	or	epoxy-resin	(55).	The	last	two	are	easy	methods	 to	 cover	 a	 diagnostics	 system	 since	 they	 allow	 human	metabolites	 to	 penetrate	 the	 packaging	 and	 reach	 the	 sensing	electrodes	 of	 the	 system.	 Figure	 9	 shows	 these	 two	 methods	 of	building	 biocompatible	 packagings	 that	 we	 have	 used	 in	 past	 to	realise	implantable	biosensing	chips	with	biocompatible	covers.	The	biocompatibility	of	the	membranes	obtained	with	such	methods	has	been	 already	 tested	 and	 published	 several	 times	 in	 literature,	 as	well	as	we	have	confirmed	with	experiment	on	mice	(10).				
System	Design	As	we	have		seen	in	all	the	previous	sections	about	the	present	state-of-the-art	in	CMOS	technology	for	heterogeneous	integration	toward	fully	 integrated	 biosensing	 systems,	 many	 already	 achieved	developments	 are	 now	pointing	 toward	 the	 direction	 of	 extremely	small-scale	devices	and	in	the	next	5	or	10	years	the	technology	will	be	 ready	 to	 bring	 to	 the	 market	 Body	 Dust	 under	 form	 of	 CMOS	active	sensing	cubes	with	 later	 sizes	of	about	10	μm3.	 In	 fact,	 even	though	it	seems	that	fully	integrated	biochips	are	now	still	limited	to	lateral	sizes	of	about	200-500	μm,	we	have	already	seen	in	literature	as	well	as	partially	demonstrated	with	our	previous	works	already	published	all	the	knowledge	and	prior	art	we	need	to	push	now	the	present	limits	well-below	100	μm	and,	therefore,	investigate	all	the	design-challenges	 required	 for	 a	 further	 step	 toward	 CMOS	diagnostics	 systems	 with	 lateral	 sized	 below	 10	 μm.	 This	 and	 the	following	sections	are	then	going	to	introduce	how	to	design	such	a	Body	 Dust	 with	 self-forming,	 self-localization,	 and	 diagnostics	capability.	
	
System	Design:	the	sensor	frontend	As	 the	 first	 step	 in	 design,	 and	 specifically	 for	 the	 system-on-chip	which	will	perform	the	sensing,	the	following	blocks	are	considered:	A	 3-electrodes	 set	 containing	 counter,	 working	 and	 reference	electrodes;	 a	 transimpedance	 amplifier,	 a	 potentiostat,	 a	 reference	block,	and	a	current	controlled	ring	oscillator.			
	
Fig.	9:	ICs	fabricated	with	multi-target	sensors	within	biocompatible	packages:	(A)	reprinted	from	(27),	and	(B)	reprinted	from	(41).	
A	possible	 complete	 system	architecture	 for	 this	 system	on	 chip	 is	shown	in	Figure	10.	Specifically,	it	is	made	up	of	the	following:	
• A	transimpedance	amplifier	(TIA)	connected	to	the	working	electrode	 to	 convert	 the	 sensor	 current	 flowing	 through	 the	working	electrode	into	a	voltage.	This	circuit	needs	to	be	high	gain,	low	noise	(sub	pA/√Hz)	and	have	a	high	dynamic	range	(>120dB)	 capable	 of	 detecting	 bi-directional	 sensor	 currents	from	 1pA-100μA.	 The	 bandwidth	 should	 allow	 operation	 of	up	 to	 100KHz	 to	 carry	 out	 cyclic	 voltammetry	 and	chronoamperometry.	 Several	 topologies	 including	 those	shown	in	Table	1	are	considered	 in	 this	design	to	achieve	the	best-required	specifications.	
• A	potentiostat	 is	 designed	 to	 be	 connected	 to	 the	 reference	electrode	and	counter	electrode.	This	circuit	needs	to	provide	a	stable	 bias	 to	 the	 reference	 electrode	 and	 have	 sufficient	bandwidth	 to	 allow	 cyclic	 voltammetry.	 An	 opamp-based	approach	 is	 used	 with	 high	 gain	 (>90dB)	 and	 bandwidth	(>100KHz),	 and	 is	 designed	 rail-to-rail	 so	 that	 it	 can	 supply	voltages	to	achieve	the	maximum	dynamic	range.	
• A	 Modulator	 implemented	 as	 a	 current	 controlled	 ring	
oscillator	 to	 convert	 the	 sensed	 current	 from	 the	 TIA	 to	 a	frequency-modulated	 signal,	 which	 drive	 the	 transmission	coils	through	backscattering.	
	
Fig.	10:	System	architecture	of	self-forming	CMOS	SoC.		
	
Fig.	11:	Aluminium	electrodes	created	on	the	surface	of	a	0.35μm	CMOS	chip,	from	(22,	56)		
• An	on-chip	receiver	and	power	rectifier	to	extract	power	and	generate	 a	 regulated	 supply	 form	 the	 signal	 received	 by	 the	coil.	This	should	be	designed	to	generate	a	supply	between	0.5-1.2V.		We	have	already	designed	a	similar	CMOS	architecture	and	related	simulations	 have	 demonstrated	 the	 possibility	 to	 realize	 such	 a	design	within	a	chip	area	of	about	111,64	μm2	(57),	which	fits	well	with	 the	aim	of	 this	paper.	On	 top	of	 such	a	CMOS	die,	 an	array	of	
aluminium	electrodes	is	formed	on	the	top	CMOS	surface	to	realise	the	 working,	 reference	 and	 counter	 electrodes,	 which	 allows	 the	platinum	 deposition.	 These	 acts	 as	 the	 sensor	 interface	 for	 the	diagnostic	 ICs.	 As	 shown	 in	 Figure	 11	 and	 referred	 to	 one	 of	 our	previous	works	(56),	aluminium	is	the	standard	metal	typically	used	in	 a	 CMOS	 process	 and	 the	 electrodes	 are	 obtained	 using	 the	 top	metal	of	the	CMOS	process.		CMOS	microchips	are	typically	passivated	on	the	top	surface	with	an	insulating	 layer	 of	 silicon	 dioxide	 to	 protect	 from	 humidity	 and	damage.	This	layer	is	etched	at	fabrication	to	allow	exposure	of	top	metal	aluminium	for	 the	purpose	of	 forming	bond	pads	to	 the	chip	usually	enabling	wire	bonding	of	gold	wires	in	order	to	interface	to	the	integrated	circuits	on	the	chip	by	using	external	electronics.	We	use	 the	same	pad	 layer	opening	 to	 form	our	 top	electrodes.	This	 is	achieved	 by	 designing	 the	 electrode-area	 by	 using	 top	 metal,	 and	then	defining	 this	 area	 as	 a	pad	 layer.	During	 fabrication,	 all	 areas	defined	 as	 pad	 layer	 is	 etched	 until	 top-metal	which	 is	 used	 as	 an	etch	 stop.	 The	 result	 is	 the	 formation	 of	 aluminium	 electrodes	 of	similarly	 in	 the	 structure	 shown	 in	 Figure	 11.	 These	 aluminium	electrodes	are	 then	directly	connected	to	 the	 integrated	circuits	by	the	underneath	metal	layers	to	form	a	complete	monolithic	solution.			
Integration	of	remote	powering	coil	For	the	integration	of	the	remote	powering	micro-coil,	two	different	strategies	 are	 considered.	 First,	 a	 coil	micro-fabricated	 is	 designed	and	 realized	 independently	 by	 the	 CMOS	 circuits	 by	 depositing	metals	 on	 silicon	 by	 using	 conventional	 lithography.	 For	 this	 first	approach,	we	propose	a	fabrication	process	we	have	already	tested.	In	fact,	we	have	already	successfully	realized,	tested,	and	published	in	2014	a	coil	micro-fabricated	directly	in	silicon	and	realized	in	the	clean	 room	 of	 EPFL	 (58),	 as	 shown	 in	 Figure	 12.	 This	 coil	 was	realized	 with	 a	 single-layer	 deposition	 by	 using	 a	 mold	 with	thickness	from	60	μm	and	it	 is	capable	to	receive	up	to	8.7	mW.	In	particular,	thin	layers	of	chromium	(20	nm)	and	gold	(100	nm)	are	evaporated	by	Joule	effect	on	the	wafer.	Then,	a	layer	of	60	μm	Ordyl	dry	 film	 is	 laminated	 on	 the	 wafers	 as	 negative	 photoresist.		Trenches	are	opened	in	the	Ordyl	film	and	copper	electro-plating	is	performed	to	deposit	the	inductor	traces.			
	
Fig	12:	SEM	image	of	evaporated	micro-coils,	reprinted	from	(58).	
	
Fig.	13:	μcoil	monolithically	obtained	in	CMOS	technology	by	metal	lines,	SEM	image	from	KAIST		Plasma	 cleaning	 and	wet	 etching	 is	 used	 to	 remove	 both	 traces	 of	organic	resists	and	sticking	layer	in	chromium	and	gold	in	order	to	obtain	 finally	 the	 single	 coil	 traces.	 The	 passivation	 (typically	 in	SiO2)	 is	 finally	deposited	to	assure	protection	of	the	coil	spires	and	the	final	structure	is	shown	in	figure	13.	Wafers	may	be	then	cut	to	
separate	the	inductors	and	aluminium	wire	bonding	used	to	connect	the	 inner	 edge	 of	 every	 inductor	 to	 the	 contact	 pad	 laying	 outside	the	spiral.	Epoxide	resin	is	applied	over	the	bonding	area	to	prevent	short-circuits.	A	 second	 strategy	 is	 instead	 considered	 by	 realizing	 the	microcoil	directly	 integrated	with	 the	CMOS	 circuit	 by	 exploiting	 the	 several	allowed	 metal	 layers.	 This	 CMOS	 fabrication	 is	 considered	 in	 two	options:	 the	 first	 option	 is	 to	 build	 the	 μcoil	 monolithically	embedded	in	the	CMOS	architecture	by	surrounding	the	metal	lines	and	vias	required	to	contact	the	sensing	electrodes	on	the	top	of	the	die,	as	well	as	in	the	structure	shown	in	Figure	13.		A	 further	 option	 is	 instead	 to	 use	 all	 the	 metal	 layers	 and	 all	 the	available	 VLSI	 area	 to	 realize	 only	 the	 coil.	 Then,	 in	 a	 post-processing	step,	 the	chip	of	 the	coil	 is	 flip	and	bonded	to	 the	other	CMOS	 chip	 where	 the	 sensing	 system	 would	 be	 independently	realized.	Both	the	options	are	considered	and	the	best	one	in	terms	of	better	system	performance	and	 fabrication	costs	may	be	chosen	for	the	final	demonstrators.		The	 advantages	 of	 the	 first	 approach	 is	 the	 degree	 of	 freedom	 in	designing	 and	 realizing	 the	 μcoil	 in	 a	 separate	 silicon	 substrate	without	CMOS	constrain	 (metals	 to	be	used,	 fabrication	sizes,	etc.),	while	the	advantages	of	the	second	approach	is	the	full	compatibility	with	the	CMOS	process	and	the	simultaneous	fabrication	of	the	coil	with	the	CMOS	circuit,	in	the	option	for	the	monolithic	integration.		Of	 course,	 in	 case	 that	 these	proposed	 strategies	 for	powering	our	CMOS	 dust	 by	 mean	 of	 an	 inductive	 link	 will	 reveal	 a	 too-low	received	energy	with	 respect	 the	power	demand	by	 the	 integrated	electronics	 for	 sensing	 and	 telemetry,	 then	 alternative	 approaches	for	 energy	 harvesting	 might	 be	 considered	 and	 suggested	 as	guidelines	 for	 creating	 sub-10μm	 CMOS	 systems	 for	 drinkable	electronics.	 For	 example,	 alternative	 approaches	 such	 as	 galvanic	processes	 involving	 intestine	 acids	 (59)	 or	 energy-recovery	 by	 the	glucose	content	in	blood	streaming	(60)	may	be	considered.		
System	Design:	the	nanosensors	
Formation	of	Au	electrodes		Recently,	 we	 have	 already	 successfully	 integrated	 nano-Pt	structures	directly	on	top	of	a	CMOS	die	as	well	(see	Figure	14)	and	succeeded	 in	 using	 the	 chip	 for	 bio-detection	 (22).	 	 By	 using	photolithography-based	techniques,	we	propose	to	create	gold	(Au)	electrodes	 above	 the	 Aluminium	 electrodes	 on	 the	 CMOS	 chip	surface.	 Gold	 is	 suitable	 because	 it	 an	 inert	 material	 that	 is	biocompatible,	 is	 relatively	 inert,	 has	 a	 relatively	 wide	electrochemical	 potential	 window,	 and	 is	 very	 commonly	 used	 in	electrochemical	 systems	 since	 it	 allows	 immobilization	 of	biomaterials.	Electrodes	are	constructed	by	 first	depositing	a	5-nm	titanium	 (Ti)	 adhesion	 layer	 under	 a	 100-nm	 gold	 (Au)	 layer	 and	patterning	the	layers	by	using	photolithography	(21).		
	
Fig	14:	SEM	images	at	different	magnification	of	nano-Pt	directly	growth	on	the	top	metal	layer	of	a	CMOS	die,	reprinted	from	(22).		
Formation	from	tetravalent	platinum	Pt	nanopetals	with	average	size	in	the	Nanoscale	(of	around	68	nm)	are	 produced	 at	 the	 exposed	 pad-electrodes.	 The	 IC	 electronics	 is	also	designed	to	be	capable	the	right	potential	 for	the	 formation	of	nanosensors	by	electrodeposition	once	the	CMOS	cube	is	exposed	to	a	 solution	 containing	 tetravalent	 platinum	 salt.	 In	 particular,	 the	chip	function	will	apply	−1V	for	200s,	meanwhile	the	IC’	electrodes	are	exposed	to	a	solution	of	25mM	H2PtCl6	and	50mM	H2SO4	(38).	To	study	alternatives	on	 forming	 the	nanosensors,	 the	 influence	of	the	 deposition	 solution	 is	 optimized	 by	 also	 considering	 different	concentrations	for	both	the	Pt	salt	(the	H2PtCl6)	and	the	H2SO4	as	well.	Ranges	of	concentrations,	e.g.	from	3mM	to	500mM	are	usually	considered	 for	 the	 case	 of	 H2PtCl6,	 while	 ranges	 from	 25mM	 to	50mM	are	usually	considered	for	the	H2SO4.	The	differently	formed	
electroactive	 areas	 on	 top	 of	 the	 IC’	 electrodes	 may	 be	 then	investigated	 by	 using	 the	 SEM	 (Scanning	 Electron	 Microscopy)	 in	order	 to	 verify	 the	 quality	 of	 the	 obtained	 nanosensors	 and	 to	investigate	 the	 different	 outputs	 obtained	 by	 the	 different	concentrations	of	species	in	the	forming	solutions.		
	
Formation	from	divalent	platinum	The	 self-formation	 of	 nanostructured	 sensor	 on	 top	 of	 our	 IC	 dies	are	 also	 optimized	 by	 using	 a	 solution	 containing	 a	 divalent	platinum	 salt:	 the	 K2PtCl4	 (again,	 in	 solution	 with	 H2SO4).	 It	 has	been	 demonstrated	 that	 the	 morphology	 we	 can	 obtain	 with	 this	different	salt	may	result	from	nanospheres	if	applying	the	voltage	of	−0.2V.	 Therefore,	 we	 also	 consider	 nanostructures	 by	 divalent	platinum	 salt	 by	 using	 the	 same	 forming	 IC	 function	 that	 apply	 a	potential	 of	 -1V	 but	 proposing	 in	 this	 series	 of	 experiments	 the	divalent	platinum	salt,	instead	of	the	tetravalent	platinum	salt	used	before.	Here,	we	can	also	suggest	to	change	solution	concentrations	in	ranges	from	25mM	to	37.5mM	for	the	K2PtCl4	(38)	too,	and	again	from	 25mM	 to	 50mM	 for	 the	 H2SO4.	 Similarly,	 the	 differently	formed	electroactive	areas	on	top	of	the	IC’	electrodes	may	be	then	investigated	by	using	again	the	SEM	in	order	to	verify	the	quality	of	the	 obtained	 nanosensors	 and	 to	 investigate	 the	 different	 outputs	obtained	 by	 the	 different	 concentrations	 of	 species	 in	 the	 forming	solutions.	 Nanostructures	with	 features	 from	 47	 nm	 to	 70	 nm	 are	expected	by	using	this	methodology	based	on	divalent	platinum	salt.	
	
Subsequent	Formations	To	further	improve	the	electroactive	area	of	the	electrodes,	we	could	also	carried	out	successive	depositions,	e.g.,	 running	 the	same	self-forming	 functions	 several	 times	 in	 series.	 For	 example,	 after	 the	deposition	 of	 nanospheres	 (e.g.,	 −1	V,	 200	 s,	 25	mM	K2PtCl4	 +	 50	mM	 H2SO4)	 we	 synthesize	 Pt	 nanopetals	 onto	 the	 overgrown	electrode	 (e.g.,	 −1	V,	 90	 s,	 25	mM	H2PtCl6	 +	 50	mM	H2SO4).	 This	output	 is	obtained	by	using	the	same	forming	function	of	 the	IC	by	exposing	the	CMOS	die	to	two	different	Pt-salt	solutions.	Therefore,	we	then	obtain	Pt	nanopetals	grown	on	nanospheres.	The	quality	of	the	obtained	 two	differently	 shaped	nanostructures	may	be,	 again,	investigated	 by	 SEM	 microscopy	 in	 order	 to	 check	 and	 verify	 the	quality	of	the	obtained	sensing	nano-structured	surfaces.		
	
System	Design:	the	biosensors	The	formation	of	the	biosensors	on	top	of	the	IC	dies	is	obtained	by	electrochemical	 deposition	 (or	 condensation)	 of	 proper	 polymer	that	 could	 traps	 the	 proteins	 on	 its	 matrix.	 In	 fact,	 the	 working	electrodes	of	the	CMOS	dye	are	individually	functionalized	with	high	precision	 with	 a	 single-step	 electrodeposition	 by	 using	 solutions	containing	 chitosan	 (61).	 As	 described	 in	 the	 previous	 sections	 of	the	state	of	the	art,	different	proteins	are	used	to	specifically	target	different	 cancer	 markers,	 and/or	 human	 metabolites,	 and/or	chemotherapeutic	 compounds.	 The	 polarization	 of	 the	 working	electrodes	at	a	certain	potential	for	a	certain	time	lap	will	creates	a	localized	 region	 of	 high	 pH	 that	 exceed	 chitosan’	 solubility	 limit,	allowing	 the	 materials	 polymerization	 and,	 therefore,	 the	entrapment	 with	 high	 spatial	 selectivity	 of	 any	 other	 compound	present	 in	 the	 solution,	 including	 the	proteins	present	 in	 the	 same	solution.	The	variation	 in	 the	electrodeposition	 time	will	 allow	 the	control	the	amount	of	deposited	proteins.	Therefore,	we	expose	the	top	 working	 electrodes	 of	 the	 die	 to	 a	 solution	 containing	 proper	proteins	and	the	chitosan,	and	the	right	function	in	the	IC	is	capable	to	 trigger	 the	 formation	 of	 the	 biosensors	 on	 top.	 To	 deposit	 the	proteins	by	chitosan	trapping,	the	forming	functions	of	the	CMOS	IC	will	provide	a	proper	potential	at	the	electrodes	where	the	sensing	film	needs	to	be	formed.	The	IC	is	exposed	for	5	min	to	a	deposition	solution.	 To	 optimize	 the	 biosensors	 performance,	 we	 consider	deposition	solution	in	the	ranges	of	concentration	of	about	0.5%	of	chitosan	 solution	 and	 ranging	 from	 10	 to	 50	 μM	 for	 the	 protein.	After	 the	 electrochemical	 deposition	 of	 the	 probe	 proteins,	 the	functionalised	CMOS	dyes	 are	 then	 rinsed	with	PBS	buffer	 at	pH	7	(to	preserve	 the	proteins’	 function)	and	stored	 in	 the	buffer	at	4	C	before	 tests.	 As	 an	 alternative,	 we	 also	 propose	 to	 consider	 a	different	 forming	 procedure	 with	 the	 aim	 to	 see	 if	 we	 can	 find	 a	better	method.	In	this	second	case,	the	electrodeposition	of	proteins	
is	 carried	 out	 in	 a	 pH	 5.6	 electroplating	 bath	 containing	 also	palladium	 to	 assure	 the	 electroplating	 and	 to	 enhance	 the	 final	biosensor	 properties	 (62).	 The	 composition	 of	 the	 palladium–protein-electroplating	bath	consists	PdCl2	and	the	probe	protein.	By	following	 the	 originally	 proposed	 procedure	 (62),	 ranges	 of	concentration	 from	0.5	 to	 3	mM	 are	 considered	 for	 the	 PdCl2	 and	from	 300	 to	 1500	 Units	 for	 the	 protein,	 in	 order	 to	 optimize	 the	performance	 of	 the	 formed	 biosensors.	 In	 this	 case,	 the	 forming	function	of	the	IC	provides	a	constant	potential	of	−0.9	V	for	10	min.			
System	Design:	Biocompatible	packaging		Packaging	 of	 the	 system	 should	 provide	 a	 special	 coating	 that	 is	biocompatible	 whilst	 allowing	 a	 series	 of	 special	 functions:	 (i)	allowing	 passing	 through	 the	 gut-wall	 barrier;	 (ii)	 targeting	 a	specific	 tumor	 mass;	 (iii)	 allowing	 human	 molecules	 (tumor	biomarkers,	 metabolites,	 and	 anti-cancer	 chemotherapy	compounds)	to	penetrate	the	packaging	for	reaching	the	sensors.	In	past,	 we	 have	 already	 realized	 and	 successfully	 tested	 several	biocompatible	packages	 for	 fully	 implantable	devices.	 In	particular,	we	have	 verified	 that	 the	use	 of	 an	 epoxy	 resin	 is	 sufficient	 to	 the	aim.	In	our	experiments	with	mice,	we	didn’t	registered	any	further	inflammation,	nor	in	terms	of	increased	neutrophils	neither	in	terms	of	 increased	 ATP	 (adenosine-triphosphate),	 with	 respect	 to	commercially	available	RFID-chip	we	normally	implanted	in	our	pet	dogs	(10).	On	the	other	hand,	the	use	of	epoxy	resin	provides	a	semi-permeable	 membrane	 that	 allows	 body	 metabolites	 to	 reach	 the	sensing	 electrode	 of	 the	 diagnostic	 device.	 Therefore,	 the	 CMOS	sensing	cube	is	covered	with	layers	of	a	membrane	made	by	epoxy-enhanced	polyurethane.	An	already	successfully	tested	procedure	is	followed	 (10):	 a	 homogeneous	 solution	 is	 obtained	 by	mixing	 125	mg	 of	 an	 epoxy	 adhesive	 (EP42HT-2Med	 system),	 purchased	 by	Master	 Bond	 (Hackensack,	 USA)	 as	 a	 certified	 biocompatible	 two-components	 adhesive,	 112.5	 mg	 of	 polyurethane	 (Sigma	 Aldrich),	12.5	mg	of	 the	 surfactant	 agent	 polyethylene	 glycol	 ether	 (Brij	 30,	Sigma	Aldrich),	for	10	ml	of	tetrahydrofuran	(THF,	Sigma	Aldrich)	is	used	 as	 solvent.	 In	 case,	 subsequent	 depositions	 of	 the	membrane	are	 applied	 at	 1	 h	 intervals	 and	 then	 the	 CMOS	 dyes	 are	 stored	overnight	at	room	temperature.	A	fast	curing	at	high	temperature	(2	h	at	80	C)	is	needed	to	ensure	the	biocompatibility	of	the	resin.	After	this	 process,	 the	 CMOS	 dyes	 are	 again	 kept	 overnight	 at	 room	temperature,	 and	 then	 stored	 in	 PBS	 one	 day	 for	 membrane	swelling.	A	successive	step	of	functionalization	on	the	surface	of	the	epoxy	resin	is	then	performed	in	order	to	transfer	proper	ligands	for	targeting	 the	 tumour	 mass.	 Target	 molecules	 that	 are	 specific	 for	tumor	 cells,	 for	 example	 prostate	 specific	 membrane	 antigens	 or	Transferrin	 receptors	 (63),	 are	 considered	 to	 identify	 the	 related	ligands,	e.g.,	small	molecules	or	antibody	fragments.	The	epoxy	resin	is	 then	 functionalized	 with	 these	 ligands	 by	 using	 conventional	linkers	 to	 bind	 the	 ligands	 to	 the	 resin.	 It	 is	 well	 known	 that	 the	amine	 (NH2)	 groups	 react	 with	 the	 epoxide	 groups	 of	 the	 resin	during	polymerisation	(64),	while	 the	structure	of	proteins,	e.g.,	an	antibody,	contains	a	lot	of	amino	acid	residues	with	exposed	amine	groups	useful	to	cross-link	with	functional	surfaces	(65).	A	final	step	of	 functionalization	 is	 done	 to	 transfer	 proper	 lipids	 into	 the	packaging	 membrane.	 This	 is	 required	 by	 the	 mechanism	 of	internalization	 by	 M	 and	 dendritic	 cells	 (12).	 Lipid	 raft	 domains	(66),	or	coatings	with	lauroyl	chains	and	propranolol	molecules	(67)	are	 both	 considered	 to	 provide	 an	 augmented	 endocytosis.	Alternative	 organic	 or	 biological	molecules	 suitable	 for	 integration	in	 the	 epoxy	 membrane	 and	 carrying	 an	 internalization	 function	may	 be	 identified	 in	 literature	 and,	 in	 case,	 integrated	 in	 the	packaging	 as	well.	 Even	 though	 it	 has	 been	 never	 tried	 (up	 to	 our	knowledge),	 a	 similar	 biocompatible	 semi-permeable	 membrane	may	be	further	functionalized	with	molecules	that	manifest	affinity	to	 specific	 receptors	 at	 the	 surface	 of	 human	 cells	 related	 to	 a	disease	 in	 order	 to	 target	 a	 specific	 body	 region.	 For	 example,	 in	case	of	a	tumor	mass,	it	is	possible	to	functionalise	such	a	membrane	with	 affinity	 ligands	 that	 target	 tumor	 cells	 as	well	 as	 it	 is	 usually	proposed	 for	active	 targeting	 in	anticancer	 therapies	 (11).	The	day	the	 technological	 progress	 will	 succeed	 in	 developing	 CMOS	diagnostics	 tool	 with	 size	 of	 very	 few	 micros,	 a	 further	 function	might	be	transferred	to	the	biocompatible	membrane:	the	capability	to	 trigger	 the	 internalization,	 a	 process	 that	 allow	 to	 pass	 the	 gut	
walls	 thank	 to	 Microfold	 (M)	 cells	 and	 dendritic	 cells	 (12).	 The	mechanism	of	 internalization	 is	a	phenomenon	of	 taking	molecules	(e.g.,	an	antigen)	from	the	lumen	to	the	intestine	(and	vice-versa)	by	means	 of	 the	 endocytosis	 and	 exocytosis.	 Endocytosis	 and	exocytosis	 are	 two	 reversed	 processes	 used	 by	 cells	 to	 engulf	molecules	and	then	provide	an	active	transport.	In	dendritic	and	M	cells,	 this	 mechanism	 also	 allow	 the	 transport	 of	 quite	 large	 bio-structures,	like	liposomes	that	can	reach	size	up	to	2.5	μm	(13).	The	process	 of	 internalisation	 is	 also	modulated	 by	 lauroyl	 chains	 and	propranolol	 molecules	 (67),	 as	 well	 as	 by	 lipid	 raft	 domains	 that	have	 shown	 an	 augmented	 endocytosis	 (66).	 Therefore,	 lipids	 are	suitable	 organic	 molecules	 to	 be	 used	 for	 transferring	 further	function	on	biocompatible	membranes	to	support	active	transports	in	biological	cells.	
	
Potential	Applications	and	Impact	of	Technology	In	this	paper	we	introduce	the	concept	of	Body	Dust,	a	new	kind	of	CMOS	 diagnostics	 in	 the	 form	 of	 dust	 particles	 integrating	bionanosensors	 for	 continuous	 monitoring	 of	 several	 human	metabolites.	Such	a	new	technology	we	are	proposing	here	will	have	a	 big	 social	 and	 economic	 impact	 on	 three	 main	 socio-economic	groups:	 IC	 industry	 (the	 industry	 of	 production	 of	 integrated	electronics),	 the	 biomedical	 circuits	 and	 systems	 community,	 and	the	pharma	industry	as	well.	
	
Microelectronics	industry	Demand	for	new	bioelectronic	systems	available	 in	the	market	will	definitely	 increase	 in	 the	 following	 years	 mainly	 due	 to	 an	expanding	 number	 of	 end-user	 applications	 based	 on	 personal	electronics	(e.g.,	smartphones,	tablets,	connected	watches,	etc).	This	will	provide	 further	stimulus	to	the	growth	of	 the	microelectronics	market	worldwide.		More	 important,	 microelectronics	 post	 processing	 becomes	 a	 key	factor	for	many	of	these	new	applications	and,	in	some	cases,	it	can	be	 cumbersome	 to	 preserve	 the	 functions	 of	 the	 underneath	architectures.	 Therefore,	 the	 global	 microelectronics	 industry	 will	benefit	 of	 the	 completely	 new	 approach	 we	 are	 proposing	 in	 this	paper	for	the	CMOS	design	as	well	as	for	the	post	processing	steps.	Nowadays,	the	post	processing	is	typically	manufactured	for	hybrid	ICs	 by	 depositing	 and	 patterning	metals	 after	 the	 chip	 fabrication.	Typical	 example	 is	 the	 post	 processing	 required	 for	 integrating	MEMS	 sensors	 (e.g.,	 accelerometers)	 and	 the	 readout	 electronics.	Our	new	approach,	will	offer	to	the	global	IC	industry	a	completely	innovative	way	to	have	formed	and	self-programmed	post	processes	deeply	integrated	in	the	CMOS	architectures	with	possibility	of	easy	formation	 of	 nanostructured	 and/or	 bio-functionalized	 electrodes	on	top	of	the	hybrid	ICs	for	many	different	applications.	
	
Biomedical	Circuits	and	Systems	In	diagnostics,	new	concepts	such	as	home	diagnostics	and	remote	monitoring	 are	 emerging.	 These	 new	 concepts	 require	 the	commercialization	of	a	completely	new	class	of	autonomous	devices.	This	 is	 reflected	 in	 the	 worldwide	 effort	 to	 develop	 healthcare	equipment	 that	 support	 portability,	 reduced	 size,	 low-power	consumption,	 low-costs	 in	 fabrication,	 easy-to-use	 or	 fully-autonomous	 functions.	 However,	 this	 is	 possible	 only	 with	 an	intimate	 integration	 with	 electronic	 architectures	 that	 provide	complex	functions,	such	as	automatic	acquisition,	processing,	fusion,	communication,	integration,	and	control	of	data.	This	new	emerging	market	 (the	worldwide	market	 for	 consumer	devices	 in	healthcare	
personal	diagnostics)	is	estimated	to	reach	US$47.40	billion	by	2020	with	 an	 annual	 growth	 rates	 for	 investments	 of	 around	 6%	 in	 the	period	 2016-2020.	 Of	 course,	 this	 market	 includes	 sensors	 for	temperature,	 blood	pressure,	 heart	 rate,	 ECG,	 blood	 glucose,	 blood	oxygen,	posture,	altitude,	motion,	and	others.	Our	new	approach	will	offer	the	global	industry	in	the	sector	of	the	personal	diagnostics	the	possibility	to	expand	to	many	other	detection	targets	and	to	obtain	integrated	 and	 highly-sensitive	 (thank	 to	 nanostructures)	diagnostics	biochip	for	different	applications.	
	
Pharmaceutical	industry	A	 relevant	 part	 of	 the	 whole	 world	 economy	 is	 driven	 by	 the	
pharmaceutical	 industry.	 Worldwide,	 the	 pharmaceutical	 industry	reached	around	US$1	trillion.	North	America	is	the	largest	portion	of	such	 market	 with	 more	 than	 40%,	 while	 new	 markets,	 e.g.	 the	Chinese	 one,	 show	 incredibly	 high	 growth	 rates	 over	 the	 last	 five	years.	Usually,	 the	pharmaceutical	 companies	 invest	nearly	around	20%	 of	 their	 revenues	 in	 research,	 development,	 and	 test	 of	 new	compounds.	 Thus,	 the	 development	 of	 completely	 new,	 low-cost,	innovative	 dust	 devices	 that	 could	 be	 spread	 in	 bioreactors	 for	continuous	monitoring	 in	 full	 autonomy	mode	 the	 production	will	offer	great	benefits	to	worldwide	pharma	industry	in	saving	money	and	 shortening	 the	 time-to-market	 for	 their	 products.	 This	 new	technology	 will	 furnish	 a	 further	 competitive	 market	 advantage,	business	development	and	raise	of	credibility	to	pharma	companies	and	providing	them	a	first-in-the-world	technology	to	monitor	their	bioreactors	with	 a	 diagnostic	 dust	 just	 spread	 in	 the	 cell	media	 as	well	as	any	other	feeding	component	of	the	cell	culture.			
Conclusions	In	 this	paper,	we	have	 introduced	 the	concept	of	a	new	CMOS	bio-sensing	technology,	which	 is	so	small	 that	 it	could	be	drinkable	 for	in-body	 diagnostics.	 The	 realisation	 has	 been	 shown	 through	 the	design	 of	 a	 CMOS	 diagnostic	 chip	 to	 form	 Body	 Dust,	 integrating	bionanosensors	 for	 continuous	 monitoring	 of	 several	 human	metabolites.	 This	 relies	 on	 all	 the	 discussed	 methodologies	 to	address	the	several	design	challenges,	which	allow	such	aggressive	miniaturisation	 using	 state	 of	 the	 art	 CMOS	 fabrication.	 	 	We	have	also	 discussed	 the	 huge	 social	 and	 economic	 potential	 impact	 of	such	a	new	technology.	Three	 main	 socio-economic	 markets,	 dealing	 with	 integrated	electronics,	 biomedical	 circuits	 and	 systems,	 and	 pharma,	 will	 get	significant	improvement	by	this	approach.	The	theoretical	basis	for	such	 an	 approach	 has	 been	 described	 in	 this	 paper,	 while	 a	 true	demonstration	 by	 means	 of	 a	 prototype	 is	 still	 in	 progress.	Furthermore,	 some	 aspects	 of	 the	 proposed	 approach	 still	 require	more	 deep	 analysis,	 e.g.	 the	 power	 transmission	 that	 allows	 us	 to	realise	receiving	coils	with	the	size	of	10	μm	in	lateral	size.	However,	we	 have	 proposed	 here	 the	 basis	 of	 such	 new	 approach	 in	diagnostics	 as	 well	 as	 we	 have	 identified	 the	 technological	challenges	which	we	need	to	address	in	order	to	make	it	real.		
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